V-184 is a Recombinant Vector Vaccine owned by Merck & Co, and is involved in 1 clinical trial, which was completed.
V-184 delivers the chikungunya antigens directly to macrophages and dendritic cells – the most potent and effective antigen-presenting cells, thereby triggering a specific immune response to chikungunya virus.
The revenue for V-184 is expected to reach a total of $139m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the V-184 NPV Report.
V-184 was originated by Themis Bioscience and is currently owned by Merck & Co.
V-184 is under development for the prophylaxis of chikungunya fever. It is a recombinant measles-virus-based vaccine. It is administered through intramuscular route as a suspention dosage form. The vaccine candidate is based on Themaxyn technology.
Merck & Co Overview
Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.
Quick View – V-184
|Highest Development Stage|